Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has treated first patient in a pivotal Phase III study of hospitalised patients with influenza which compares intravenous (IV) Zanamivir to oral Oseltamivir.
Subscribe to our email newsletter
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of Influenzavirus A and Influenzavirus B.
Oseltamivir is an antiviral drug that slows the spread of influenza (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell.
The primary endpoint of this study is time to clinical response in patients with confirmed influenza.
GSK is expecting to recruit around 462 patients in the trial.